Rituximab in the treatment of primary membranous nephropathy: a Health Economic Model

David Meads has published a decision analytic model comparing the cost-effectiveness of rituximab versus the modified Ponticelli regimen in the NHS

Hamilton P, Kanigicherla D, Venning M, Brenchley P, Meads D. Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model. Nephrol Dial Transplant. 2018 Mar 29. doi: 

10.1093/ndt/gfy049. [Epub ahead of print]